Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
Phase 1
Active, not recruiting
- Conditions
- Melanoma (Skin)Non-Small-Cell Lung Carcinoma
- Interventions
- Biological: GAd-PEVBiological: MVA-PEV
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Nouscom SRL
- Target Recruit Count
- 34
- Registration Number
- NCT04990479
- Locations
- 🇪🇸
Instituto de Investigación Sanitaria INCLIVA - Hospital Clínico Universitario de Valencia. Av. Blasco Ibáñez, 17 CP 46010 Valencia, Spain, Valencia, Spain
🇬🇧Cancer Research UK Edinburgh Centre. Western General Hospital, Edinburgh, EH4 2SP, UK, Edinburgh, Scotland, United Kingdom
🇪🇸Institut Catalá d'Oncologia ICO L'Hospitalet. Av Gran Via de L'Hospitalet 199-203. 08908 L'Hospitalet de Llobregat, Barcelona, Spain, Barcelona, Spain
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- Biological: GAd-209-FSP high doseBiological: GAd-209-FSP low doseBiological: GAd20-209-FSP, RP2DBiological: MVA-209-FSP high doseBiological: MVA-209-FSP low doseBiological: MVA-209-FSP, RP2DDrug: KEYTRUDA®
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Nouscom SRL
- Target Recruit Count
- 115
- Registration Number
- NCT04041310
- Locations
- 🇧🇪
Centre Hospitalier de l'Ardenne - Libramont - Clinique du Sein, Libramont, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇨🇦Mount Sinai Hospital, Toronto, Canada
© Copyright 2025. All Rights Reserved by MedPath